CD200 and cancer: Results indicate a stronger binding of 4a-Cu-G3 with HCT cancer cells with respect to the MRC normal cells, corroborating the lower sensitivity of the normal (EPC and MCR5) cells to 4a-Cu-G3, compared to cancer cells, as indicated just above.